Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Performance status score: do patients and their oncologists agree?

Blagden SP. et al, (2003), Br J Cancer, 89, 1022 - 1027

Polar expeditions--provisioning the centrosome for mitosis.

Blagden SP. and Glover DM., (2003), Nat Cell Biol, 5, 505 - 511

BDS Melanoma Guidelines.

Middleton M. et al, (2003), Br J Dermatol, 148, 1081 - 1082

Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway.

Middleton MR. and Margison GP., (2003), Lancet Oncol, 4, 37 - 44

Brain metastases in melanoma: a European perspective.

Cattell E. et al, (2002), Semin Oncol, 29, 513 - 517

Assessing outcomes in palliative chemotherapy.

Cattell E. et al, (2002), Expert Opin Pharmacother, 3, 693 - 700

Toxicity of temozolomide with response modifiers in metastatic malignant melanoma

Lorigan P. et al, (2002), BRITISH JOURNAL OF CANCER, 86, S68 - S68

Temozolomide: a novel oral alkylating agent.

Danson SJ. and Middleton MR., (2001), Expert Rev Anticancer Ther, 1, 13 - 19

Adjuvant interferon in melanoma - a resurrection?

Middleton MR. and Thatcher N., (2001), Br J Cancer, 84, 1141 - 1142